Los Angeles, February 2025
The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research. This year, Kari L. Kendra, MD, PhD from The Ohio State University delivered a transformative presentation on desmoplastic melanoma (DM). This rare subtype of melanoma is characterized by its presence in high sun-exposed areas with extensive UV damage and a high tumor mutational burden. It is emerging as a pivotal focus in immunotherapy innovation. Dr. Kendra’s insights, shared with a global audience of researchers and clinicians, highlight why DM is achieving unprecedented response rates. They also present what this means for the future of cancer care.
Understanding Desmoplastic Melanoma: A Unique Challenge
Desmoplastic melanoma, accounting for approximately 4% of cutaneous melanomas, is typically found in sun-damaged regions of the skin, such as the head, neck, or extremities. Its high tumor mutational burden—driven by cumulative UV exposure—makes it particularly responsive to immunotherapy. Dr. Kendra explained that this subtype’s distinctive feature, desmoplasia (an excessive fibrous tissue growth), is surrounded by an inflammatory state. This likely plays a critical role in its high treatment response rates. This biological complexity sets DM apart from other melanoma types, offering a unique opportunity for targeted therapies.
The SWOG S1512 Trial: Unprecedented Response Rates
A centerpiece of Dr. Kendra’s presentation was the SWOG S1512 phase II trial, which showcased the efficacy of single-agent anti-PD-1 therapy, such as pembrolizumab, in desmoplastic melanoma patients. The trial’s findings are nothing short of remarkable. For patients with unresectable, metastatic DM (Cohort B), the overall response rate reached an astonishing 89%, with a complete response rate of 33%. Even more impressively, resectable patients (Cohort A) with early-stage or locally recurrent disease achieved a 57% pathological complete response rate. This was after just three cycles—spanning only nine weeks—of treatment. These results underscore DM’s exceptional sensitivity to PD-1 blockade, positioning it as a model for immunotherapy success.
Treatment Strategies: Resectable vs. Unresectable Cohorts
Dr. Kendra detailed the trial’s design, emphasizing the distinction between resectable and unresectable cohorts. Resectable patients, with early or locally recurrent disease, received three treatments every three weeks before undergoing surgery. This approach leveraged the therapy’s rapid efficacy. In contrast, unresectable patients, facing distant metastatic disease (e.g., in the lungs or other sites), required longer treatment durations due to the advanced nature of their condition. Both groups received similar regimens. However, the extended treatment for unresectable cases reflected the greater disease burden. Yet it still yielded an 89% overall response rate over time.
Navigating Treatment Duration and Patient Decisions
One of the trial’s key insights was the practical management of treatment duration. Originally planned for two years, most patients stopped after one year. This was driven by the absence of clinical evidence of disease and concerns about potential toxicities, such as immune-related adverse events. Dr. Kendra noted that some patients also discontinued due to side effects, but very few continued beyond a year. This flexibility highlights the balance between efficacy and patient well-being, ensuring treatments are both effective and tolerable.
Safety Profile: A Focus on Melanoma-Specific Survival
Safety was another critical focus of Dr. Kendra’s presentation. Out of all trial participants, only one death was directly attributed to melanoma, resulting in a 96% melanoma-specific survival rate. Most other deaths were linked to comorbidities common in the trial’s median age group of 75. These included cardiac disease, pulmonary fibrosis, stroke, and falls from accidents like CNS bleeds. This safety profile reinforces the efficacy of single-agent anti-PD-1 therapy. It demonstrates minimal melanoma-related mortality and a robust survival outlook for DM patients.
Clinical vs. Pathological Responses: Unpacking the Data
Dr. Kendra also addressed the discrepancy between clinical and pathological response rates, a common phenomenon in neoadjuvant trials. She explained that while pathological responses (e.g., 57% complete response in resectable cases) often outpace clinical responses, the latter can lag due to lingering scar tissue left after tumor death. This tissue requires time to clear. In Cohort B, tracking maximal responses over time led to the 89% overall response rate. This offered a clearer picture of long-term outcomes and the therapy’s sustained impact.
Future Directions: Desmoplastic Melanoma as a Biomarker
Looking forward, Dr. Kendra proposed a paradigm shift in melanoma treatment by using desmoplastic melanoma as a biomarker. This approach could enable personalized therapies, reducing the need for aggressive multi-drug regimens and their associated toxicities. For DM patients, single-agent anti-PD-1 therapy has shown dramatic and durable responses—some persisting for three years. This suggests that less intensive treatments could suffice for this subgroup. This strategy aligns with broader efforts to improve overall response rates in cutaneous melanoma. By tailoring treatments to specific patient populations, we minimize unnecessary risks.
Why Los Angeles? A Hub for Immunotherapy Innovation
The choice of Los Angeles as the host city for AACR IO 2025 underscores its growing role as a hub for medical innovation. Despite challenges like devastating fires, the city’s vibrant downtown—near LA Live and numerous attractions—offers an ideal setting for bringing together global experts like Dr. Kendra. AACR IO 2025 continues to foster collaboration. This drives advancements in cancer research and immunotherapy that could reshape patient care worldwide.
Join the Conversation at AACR IO 2025
AACR IO 2025 is not just a conference—it’s a movement toward the future of cancer treatment. Dr. Kendra’s presentation highlights the potential for desmoplastic melanoma to lead the way in immunotherapy. This offers hope for patients and new research pathways for clinicians. We invite the global research community to engage with these findings, attend future AACR events, and contribute to the ongoing revolution in melanoma care.
Related Articles: